Neeraj Singh1, Hrishikesh Samant2, Alan Hawxby3, Millie D Samaniego4. 1. Division of Nephrology and Hypertension. 2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, LSU Health Shreveport School of Medicine, Shreveport, Louisiana. 3. Division of Transplant Surgery, University of Oklahoma, Oklahoma City, Oklahoma. 4. Division of Nephrology, Department of Internal Medicine, Henry Ford Health System, Detroit, Michigan, USA.
Abstract
PURPOSE OF REVIEW: To provide an update of the literature on the use of new biomarkers of rejection in kidney transplant recipients. RECENT FINDINGS: The kidney allograft biopsy is currently considered the gold standard for the diagnosis of rejection. However, the kidney biopsy is invasive and could be indeterminate. A significant progress has been made in discovery of new biomarkers of rejection, and some of them have been introduced recently for potential use in clinical practice including measurement of serum donor-derived cell free DNA, allo-specific CD154 + T-cytotoxic memory cells, and gene-expression 'signatures'. The literature supports that these biomarkers provide fair and reliable diagnostic accuracy and may be helpful in clinical decision-making when the kidney biopsy is contraindicated or is inconclusive. SUMMARY: The new biomarkers provide a promising approach to detect acute rejections in a noninvasive way.
PURPOSE OF REVIEW: To provide an update of the literature on the use of new biomarkers of rejection in kidney transplant recipients. RECENT FINDINGS: The kidney allograft biopsy is currently considered the gold standard for the diagnosis of rejection. However, the kidney biopsy is invasive and could be indeterminate. A significant progress has been made in discovery of new biomarkers of rejection, and some of them have been introduced recently for potential use in clinical practice including measurement of serum donor-derived cell free DNA, allo-specific CD154 + T-cytotoxic memory cells, and gene-expression 'signatures'. The literature supports that these biomarkers provide fair and reliable diagnostic accuracy and may be helpful in clinical decision-making when the kidney biopsy is contraindicated or is inconclusive. SUMMARY: The new biomarkers provide a promising approach to detect acute rejections in a noninvasive way.
Authors: Samantha E Halpern; Dimitrios Moris; Brian I Shaw; Madison K Krischak; Danae G Olaso; Samuel J Kesseli; Kadiyala Ravindra; Lisa M McElroy; Andrew S Barbas Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155
Authors: Maria Butiu; Bogdan Obrisca; Lena Sibulesky; Ramasamy Bakthavatsalam; Kelly D Smith; Idoia Gimferrer; Paul Warner; Gener Ismail; Nicolae Leca Journal: Transplant Direct Date: 2022-01-26
Authors: Bogdan Obrișcă; Maria Butiu; Lena Sibulesky; Ramasamy Bakthavatsalam; Kelly D Smith; Idoia Gimferrer; Paul Warner; Gener Ismail; Nicolae Leca Journal: Sci Rep Date: 2022-09-05 Impact factor: 4.996
Authors: Francesco Guzzi; Luigi Cirillo; Elisa Buti; Francesca Becherucci; Carmela Errichiello; Rosa Maria Roperto; James P Hunter; Paola Romagnani Journal: Int J Mol Sci Date: 2020-09-19 Impact factor: 5.923